title: Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
abstract: BACKGROUND
  The purpose of this study was to retrospectively analyze the relationship between neo-adjuvant chemotherapy (NAC) and outcome in patients with high-grade extremity sarcomas.
  
  
  METHODS
  Inclusion criteria were high-grade, deep, >5 cm extremity soft tissue sarcomas. Patients diagnosed between 1990 and 2001 were treated with surgery only (n=282) or NAC containing doxorubicin/ifosfamide/mesna (AIM) (n=74). The stratified Cox proportional hazards model was used to test the effect of NAC on disease-specific survival and recurrence while adjusting for known prognostic factors.
  
  
  RESULTS
  NAC was associated with improved disease-specific survival for this cohort of patients (P=0.02). This overall improvement appears to be driven by the benefit of NAC on disease-specific survival for patient with tumors >10 cm. The 3-year disease-specific survival for tumors >10 cm was 0.62 (95% CI: 0.53-0.71) for patients not receiving NAC and 0.83 (95% CI: 0.72-0.95) for patients receiving NAC.
  
  
  CONCLUSIONS
  NAC with AIM was associated with a significant improvement in disease-specific survival in patients with high-grade extremity soft tissue sarcomas >10 cm. These data emphasize the need for further prospective clinical studies of neo-adjuvant or adjuvant chemotherapy for patients with large high-grade extremity sarcomas.
authors.affiliation: Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Grobmyer
authors.forename: R G
authors.initials: RG
authors.lastname: Maki
authors.forename: G D
authors.initials: GD
authors.lastname: Demetri
authors.forename: M
authors.initials: M
authors.lastname: Mazumdar
authors.forename: E
authors.initials: E
authors.lastname: Riedel
authors.forename: M F
authors.initials: MF
authors.lastname: Brennan
authors.forename: S
authors.initials: S
authors.lastname: Singer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D005121:Extremities; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D015080:Mesna / Q000008:administration & dosage; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015080:Mesna; D007069:Ifosfamide